These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 19006188)

  • 1. Selective MAO-B inhibitors have low potential for the tyramine effect.
    Isaacson SH
    Mov Disord; 2010 Jan; 25(1):123-4. PubMed ID: 19006188
    [No Abstract]   [Full Text] [Related]  

  • 2. The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge?
    Chen JJ; Wilkinson JR
    J Clin Pharmacol; 2012 May; 52(5):620-8. PubMed ID: 21628600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline.
    deMarcaida JA; Schwid SR; White WB; Blindauer K; Fahn S; Kieburtz K; Stern M; Shoulson I; ;
    Mov Disord; 2006 Oct; 21(10):1716-21. PubMed ID: 16856145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
    Guay DR
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation.
    Youdim MB; Weinstock M
    Neurotoxicology; 2004 Jan; 25(1-2):243-50. PubMed ID: 14697899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of various monoamine oxidase (MAO) inhibitors on the response of blood pressure of rats and cats to tyramine.
    Abdo-Rubo A
    Acta Physiol Hung; 1990; 75(4):321-36. PubMed ID: 2127505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MAO type B inhibitors as adjunct to L-dopa therapy.
    Youdim MB; Finberg JP
    Adv Neurol; 1987; 45():127-36. PubMed ID: 3103383
    [No Abstract]   [Full Text] [Related]  

  • 9. Mao-B inhibitor know-how: back to the pharm.
    Burke WJ
    Neurology; 2009 Dec; 73(23):2048; author reply 2048. PubMed ID: 19996086
    [No Abstract]   [Full Text] [Related]  

  • 10. [Monoamine oxidase inhibitors and pressor response to dietary amines].
    Tipton KF
    Vopr Med Khim; 1997; 43(6):494-503. PubMed ID: 9503566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MAO-B inhibitor know-how: back to the pharm.
    Lewitt PA
    Neurology; 2009 Apr; 72(15):1352-7. PubMed ID: 19365057
    [No Abstract]   [Full Text] [Related]  

  • 12. MAO inhibitors.
    Keller D
    Cleve Clin J Med; 2011 Feb; 78(2):81; author reply 81. PubMed ID: 21365960
    [No Abstract]   [Full Text] [Related]  

  • 13. [Rasagiline. A new monoamine oxidase b inhibitor for Parkinson treatment].
    Oberpichler-Schwenk H
    Med Monatsschr Pharm; 2005 Jul; 28(7):224-7. PubMed ID: 16038119
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease.
    Chen JJ; Swope DM
    J Clin Pharmacol; 2005 Aug; 45(8):878-94. PubMed ID: 16027398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elucidating the mechanism of action and potential interactions of MAO-B inhibitors.
    Bainbridge JL; Page RL; Ruscin JM
    Neurol Clin; 2008 Aug; 26(3 Suppl):S85-96, vi. PubMed ID: 18774444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective pressor enhancement by monoamine oxidase inhibitors in conscious rats.
    Kerecsen L; Bunag RD
    J Pharmacol Exp Ther; 1989 Nov; 251(2):645-9. PubMed ID: 2509682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.
    Fernandez HH; Chen JJ
    Pharmacotherapy; 2007 Dec; 27(12 Pt 2):174S-185S. PubMed ID: 18041937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Rasagiline is not for all Parkinson disease patients: the ADAGIO study].
    van Laar T; Boon AJ; Bloem BR
    Ned Tijdschr Geneeskd; 2010; 154():A2496. PubMed ID: 20977789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MDL 72,974A: a selective MAO-B inhibitor with potential for treatment of Parkinson's disease.
    Palfreyman MG; McDonald IA; Zreika M; Cremer G; Haegele KD; Bey P
    J Neural Transm Suppl; 1993; 40():101-11. PubMed ID: 8294896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity.
    Bartl J; Müller T; Grünblatt E; Gerlach M; Riederer P
    J Neural Transm (Vienna); 2014 Apr; 121(4):379-83. PubMed ID: 24272680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.